Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Infection, Inflammation and Rheumatology
share announcement

Infection, Inflammation and Rheumatology

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: 29 November 2024 | Viewed by 582

Special Issue Editor

Dr. Arvind Nune

E-Mail
Guest Editor
Department of Rheumatology, Southport and Ormskirk NHS Trust, Southport, UK
Interests: infection; inflammation; autoimmunity; various rheumatic diseases

Special Issue Information

Dear Colleagues,

We are excited to announce a forthcoming Special Issue that explores infection, inflammation, and rheumatology and investigates the intricate connections between the immune system, infections, and vaccinations that lead to inflammation and associated rheumatic conditions. This comprehensive edition aims to shed light on the latest advancements, challenges, and innovative approaches within this multifaceted landscape.

Infections and autoimmune responses, particularly in the context of COVID-19 and vaccinations, have underscored the complexities in diagnosis, treatment, and management. This Special Issue will delve into a range of autoimmune disorders, such as rheumatoid arthritis, lupus, and vasculitides, while emphasizing their underlying mechanisms, genetic predispositions, and possible links to infectious agents like COVID-19.

The Special Issue will showcase cutting-edge research methodologies, diagnostic tools, and therapeutic interventions aimed at enhancing patient outcomes. Contributions exploring novel biomarkers, personalized medicine approaches (including vaccination strategies), and emerging treatments (such as biologics and immunotherapies) will be pivotal in this discourse.

We invite researchers, clinicians, and experts in the field to contribute their insights, research findings, and perspectives to this Special Issue and unravel the complexities of autoimmune diseases in rheumatology, striving toward enhanced understanding, improved therapies, and better outcomes for affected individuals.

Dr. Arvind Nune
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • infection
  • COVID-19
  • inflammation
  • vaccination
  • rheumatic diseases

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 1139 KiB  
Article
A Comparative Study on the Pain Threshold Experienced by Fibromyalgia Patients Following Acute SARS-CoV-2 Infection
by Daniela Matei, Rodica Traistaru, Anca Maria Amzolini, Laura Simona Ianosi, Carmen Daniela Neagoe, Adina Mitrea, Diana Clenciu and Taina Elena Avramescu
Life 2024, 14(8), 942; https://doi.org/10.3390/life14080942 - 27 Jul 2024
Viewed by 336
Abstract
Significant gaps remain in the understanding of the etiology and pathogenesis of fibromyalgia (FM), and the COVID-19 pandemic has introduced even more unknowns. Social factors specific to that period, the viral infection itself, and/or vaccination are additional elements that can complicate the progression [...] Read more.
Significant gaps remain in the understanding of the etiology and pathogenesis of fibromyalgia (FM), and the COVID-19 pandemic has introduced even more unknowns. Social factors specific to that period, the viral infection itself, and/or vaccination are additional elements that can complicate the progression of the disease or the response to treatment. Aim: The primary hypothesis to be evaluated in this study is that an acute COVID-19 infection, even when considered recovered, may induce changes in the response to non-pharmacological treatment in FM patients, particularly concerning pain. Results: We included 128 patients diagnosed with FM before the pandemic began. The patients were divided based on their history of acute SARS-CoV-2 infection and COVID-19 vaccination status. All patients followed the same rehabilitation program (cognitive therapy, kinesitherapy). Perceived pain: The non-COVID-19 patient groups showed a statistically significant reduction in pain at the final evaluation compared to patients with a history of acute SARS-CoV-2 infection (p < 0.001). Algometric evaluation: Patients without COVID-19 infection and that were vaccinated exhibited the best improvement in pain threshold, both across evaluation times (p < 0.001) and compared to any of the other three groups studied (p < 0.001). Using the WHYMPI questionnaire, the same group of patients (those not having experienced acute COVID-19 and who were vaccinated) was the only group with a statistically significant improvement in pain severity (p = 0.009). In conclusion, to control and improve FM pain symptoms, in addition to appropriate medication, we propose paying additional attention to the history of acute SARS-CoV-2 infection and the COVID-19 vaccination status. Full article
(This article belongs to the Special Issue Infection, Inflammation and Rheumatology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop